Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.-Reference-Cited by-同舟云学术

Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Published:2012-10 Issue:37 Volume:16 Page:
ISSN:1366-5278
Container-title:Health Technology Assessment
language:en
Short-container-title:Health Technol Assess

Author:

Papaioannou D¹,Rafia R,Rathbone J,Stevenson M,Buckley Woods H,Stevens J

Affiliation:

1. School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Funder

Health Technology Assessment programme

Publisher

National Institute for Health Research

Subject

Health Policy

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients with Advanced Follicular Lymphoma: A Cost Analysis;Farmeconomia. Health economics and therapeutic pathways;2022-11-07

2. Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris;JAMA Dermatology;2022-09-01

3. Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer;Canadian Medical Association Journal;2021-10-11

4. A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma;Leukemia & Lymphoma;2021-07-29

5. Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis;ClinicoEconomics and Outcomes Research;2021-07